Sleep Homeostasis in Primary Insomnia Following Behavioral Treatment
About 10% of the population is believed to suffer from Primary Insomnia. It is also believed that people with chronic insomnia have a sleep system that is essentially out of alignment (we call this "homeostatic dysregulation"). We also know that a certain form of non-medication therapy called cognitive-behavioral therapy is a very effective treatment for insomnia. It is not known, however, whether cognitive-behavioral therapy actually works by bringing the brain's sleep system back into alignment ("sleep homeostasis"). One of the methods used to measure sleep homeostasis is to observe a person's brain waves during sleep and particularly during sleep that follows a period of sleep loss.
The purposes of this study are to first learn whether persons with insomnia do have a misaligned sleep system compared to persons who do not have insomnia by assessing the sleep of people before and after a period of extended sleep loss. Second, the study will determine whether cognitive-behavioral therapy can re-regulate the sleep system and its response to sleep loss. Third, the final purpose is to examine whether the immune system of people with insomnia is more altered following sleep loss than in the comparison group and whether cognitive-behavioral therapy can alter immune function.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Sleep Homeostasis in Primary Insomnia Following Behavioral Treatment|
- Mean sleep latency, % total recovery sleep time, and Slow Wave Sleep (SWS) and mean NREM delta power. [ Time Frame: November 2008 ] [ Designated as safety issue: No ]
- SWS response to sleep deprivation, and cortical (Beta/Gamma power) and somatic arousal (cortisol). [ Time Frame: November 2008 ] [ Designated as safety issue: No ]
- Sleep homeostasis, cortical arousal, and somatic arousal (at Phase 3) in PIs. [ Time Frame: November 2008 ] [ Designated as safety issue: No ]
- Assessment of circadian distribution of somatic (cortisol) and cortical (Beta/Gamma EEG) arousal in association with sleep deprivation. [ Time Frame: November 2008 ] [ Designated as safety issue: No ]
- Evaluation of the 24-hour distribution of somatic (cortisol) and cortical (Beta/Gamma EEG) arousal in PIs. [ Time Frame: November 2008 ] [ Designated as safety issue: No ]
|Study Start Date:||December 2005|
|Study Completion Date:||December 2008|
|Primary Completion Date:||December 2008 (Final data collection date for primary outcome measure)|
Behavioral: Cognitive-Behavioral Therapy for Insomnia
Despite the magnitude of the problem of Primary Insomnia, and the good efficacy of Cognitive Behavioral Treatment for Insomnia (CBT-I), little is known about the pathophysiology of insomnia or whether treatment alters the factors that are thought to maintain chronic insomnia. Three main factors have been explored as contributing to chronic insomnia: hyperarousal, circadian dysrhythmia, and homeostatic dysregulation. Most of the empirical work has been related to the role of hyperarousal along three dimensions: somatic, cognitive, and cortical.
The present study is focused on homeostatic abnormalities and secondarily on hyperarousal as exhibited in subjects with Primary Insomnia (PIs) compared to Good Sleeper controls (GSs). Homeostatic abnormalities will be assessed by evaluating how patients with insomnia respond to sleep deprivation.
This study will use a Modified Sleep Deprivation and Multiple Sleep Latency Test (MSD/MSLT) procedure. Response to the procedure will be assessed in terms of sleep continuity, sleep architecture and electroencephalographic (EEG) power spectral changes during recovery sleep. Hyperarousal will be evaluated using serial measures of somatic (cortisol) and cortical (EEG Beta/Gamma activity) arousal across the sleep deprivation protocol.
These parameters will be evaluated both prior to and following CBT-I in PIs and following an equivalent time interval in GSs.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00256503
|United States, New York|
|University of Rochester Medical Center|
|Rochester, New York, United States, 14642|
|Principal Investigator:||Wilfred R. Pigeon, Ph.D.||University of Rochester|
|Principal Investigator:||Michael L. Perlis, Ph.D.||University of Rochester|